Diamond Equity Predicts MAIA Biotechnology FY2026 Earnings

MAIA Biotechnology, Inc. (NYSEAMERICAN:MAIA – Free Report) – Stock analysts at Diamond Equity upped their FY2026 earnings estimates for shares of MAIA Biotechnology in a research report issued on Thursday, November 12th. Diamond Equity analyst H. Diamond now anticipates that the company will earn ($0.48) per share for the year, up from their previous forecast of ($0.54). The consensus estimate for MAIA Biotechnology’s current full-year earnings is ($0.54) per share. Diamond Equity also issued estimates for MAIA Biotechnology’s Q4 2026 earnings at ($0.09) EPS, Q1 2027 earnings at ($0.14) EPS, Q2 2027 earnings at ($0.14) EPS, Q3 2027 earnings at ($0.10) EPS, Q4 2027 earnings at ($0.06) EPS and FY2027 earnings at ($0.44) EPS.

MAIA Biotechnology Trading Up 1.0%

MAIA opened at $1.01 on Tuesday. The company’s 50 day moving average is $1.18 and its 200 day moving average is $1.40. The company has a market cap of $62.37 million, a price-to-earnings ratio of -2.15 and a beta of 0.28. MAIA Biotechnology has a 12-month low of $0.87 and a 12-month high of $3.19.

MAIA Biotechnology (NYSEAMERICAN:MAIA – Get Free Report) last issued its quarterly earnings data on Monday, November 9th. The company reported ($0.12) earnings per share for the quarter, topping the consensus estimate of ($0.13) by $0.01.

Institutional Investors Weigh In On MAIA Biotechnology

Several hedge funds and other institutional investors have recently modified their holdings of the stock. Centric Wealth Management bought a new position in MAIA Biotechnology in the 2nd quarter worth $1,107,000. Cable Car Capital LP purchased a new position in MAIA Biotechnology during the second quarter valued at $741,000. BlackRock Inc. purchased a new position in MAIA Biotechnology during the second quarter valued at $580,000. Marshall Wace LLP purchased a new position in MAIA Biotechnology during the third quarter valued at $100,000. Finally, Empowered Funds LLC bought a new stake in MAIA Biotechnology during the third quarter valued at about $88,000. 5.65% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other MAIA Biotechnology news, Director Ramiro Guerrero purchased 37,595 shares of the company’s stock in a transaction dated Thursday, September 10th. The shares were acquired at an average price of $1.32 per share, for a total transaction of $49,625.40. Following the purchase, the director directly owned 773,296 shares of the company’s stock, valued at $1,020,750.72. The trade was a 5.11% increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Vlad Vitoc acquired 73,000 shares of the business’s stock in a transaction dated Monday, September 14th. The shares were acquired at an average cost of $1.37 per share, with a total value of $100,010.00. Following the transaction, the chief executive officer owned 1,049,121 shares in the company, valued at approximately $1,437,295.77. This trade represents a 7.48% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Over the last ninety days, insiders have acquired 258,078 shares of company stock valued at $352,426. 19.81% of the stock is owned by corporate insiders.

About MAIA Biotechnology

(Get Free Report)

MAIA Biotechnology is a clinical-stage biopharmaceutical company focused on developing cancer treatments. Its research centers on therapies that target telomeres, protective structures at the ends of chromosomes that can help cancer cells continue to divide. The company’s lead drug candidate, ateganosine (also known as THIO or 6-thio-dG), is designed to disrupt telomeres in cancer cells and promote their death. MAIA has evaluated ateganosine in clinical research, including studies involving patients with advanced non-small cell lung cancer and treatment in combination with the immunotherapy cemiplimab.

See Also

Earnings History and Estimates for MAIA Biotechnology (NYSEAMERICAN:MAIA)

Receive News & Ratings for MAIA Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MAIA Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.